Epoetin Theta
drugOn this page
Also known as BiopoinEpoetina zetaEpoetine thetaEporatio
Summary
Epoetin Theta (CHEMBL2108290) is an approved protein; indicated across 2 conditions including chronic kidney disease and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 2 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108290 |
| Name | Epoetin Theta |
| Type | Protein |
| Max phase | 4 |
Also known as: Biopoin, Epoetin theta, Epoetina zeta, Epoetine theta, Eporatio, EPOETIN THETA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: chronic kidney disease, anemia